title: Biological response modifiers (BRM), chemotherapy, and activated cytotoxic leukocyte subsets: strategies for rational design of apheresis-based cancer immunotherapies.
authors.affiliation: National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
authors.forename: H C
authors.initials: HC
authors.lastname: Stevenson
authors.forename: H G
authors.initials: HG
authors.lastname: Klein
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001781:Blood Component Removal; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007116:Immunization, Passive; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods*; D007962:Leukocytes / Q000276:immunology; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D007155:Immunologic Factors